512 Aktienübersicht Die Grand Pharmaceutical Group Limited, eine Investment-Holdinggesellschaft, ist in der Forschung und Entwicklung, der Herstellung und dem Verkauf von pharmazeutischen Präparaten und medizinischen Geräten, Biotechnologie- und Gesundheitsprodukten sowie pharmazeutischen Rohstoffen tätig. Mehr Details
Belohnungen Risikoanalyse Bei unseren Risikoprüfungen wurden keine Risiken für 512 festgestellt.
Alle Risikoprüfungen anzeigen Community vs My Fair Value Select a narrative for quick price alerts from the community, or create your own.
Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Grand Pharmaceutical Group Limited Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Grand Pharmaceutical Group Historische Aktienkurse Aktueller Aktienkurs HK$4.80 52-Wochen-Hoch HK$5.62 52-Wochen-Tief HK$3.35 Beta 0.71 1 Monat Veränderung 10.85% 3 Monate Veränderung 10.60% 1 Jahr Veränderung 31.51% 3 Jahre Veränderung -23.08% 5 Jahre Veränderung -2.83% Veränderung seit IPO -81.54%
Aktuelle Nachrichten und Updates
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02 Weitere Updates anzeigen
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 28
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough Sep 19
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Executive Chairman recently bought HK$526k worth of stock Jun 21
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year Jun 05
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Executive Chairman recently bought HK$271k worth of stock May 25
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings May 22
Executive Chairman recently bought HK$489k worth of stock May 11
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26 Apr 25
Executive Chairman recently bought HK$371k worth of stock Apr 21
Executive Chairman recently bought HK$243k worth of stock Apr 06
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26 Mar 25
Dividend increased to HK$0.26 Mar 25
Executive Chairman recently bought HK$381k worth of stock Mar 22
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings: EPS misses analyst expectations Mar 21
Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt Oct 20
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching Sep 26
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 12
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14 Jun 04 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.9% yield Jun 02 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment? May 05
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Investor sentiment improved over the past week Dec 29
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly Nov 21
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 07
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount? Sep 05
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly Aug 16
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching Jul 28
Executive Director recently bought HK$535k worth of stock Jun 10
Upcoming dividend of HK$0.11 per share May 30
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11 May 29
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount? Apr 08
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet Mar 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Now 21% undervalued after recent price drop Mar 07
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
Investor sentiment deteriorated over the past week Jan 27
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late Jan 24
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely Dec 13
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price Nov 27
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting Oct 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly Sep 01
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 11
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Investor sentiment deteriorated over the past week Jul 27
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention? Jul 12
Executive Deputy Chairman Bo Hu has left the company Jun 09
Executive Chairman Chengwei Liu has left the company Jun 09
China Grand Pharmaceutical and Healthcare Holdings Limited Announces TLX591-CDx Dosed the First Patient in Japan Jun 03
China Grand Pharmaceutical and Healthcare Holdings Limited Declares Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on June 1, 2021 Jun 02 Aktionärsrenditen 512 HK Pharmaceuticals HK Markt 7D 4.6% 6.7% 3.2% 1Y 31.5% 1.5% 23.6%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 512 übertraf die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von 1.5 erzielte.
Rendite vs. Markt: 512 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von 23.6 erzielte.
Preisvolatilität Is 512's price volatile compared to industry and market? 512 volatility 512 Average Weekly Movement 3.6% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 6.5% 10% most volatile stocks in HK Market 13.9% 10% least volatile stocks in HK Market 3.1%
Stabiler Aktienkurs: 512 hatte in den letzten 3 Monaten im Vergleich zum Hong Kong -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 512Die wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Die Grand Pharmaceutical Group Limited, eine Investment-Holding, ist in der Forschung und Entwicklung, der Herstellung und dem Verkauf von pharmazeutischen Präparaten und medizinischen Geräten, Biotechnologie- und Gesundheitsprodukten sowie pharmazeutischen Rohstoffen tätig. Das Unternehmen bietet Produkte in den Bereichen Atemwegserkrankungen, Augenheilkunde, zerebro-kardiovaskuläre Notfälle und Biotechnologie an. Es produziert und vertreibt Produkte aus den Bereichen Pharmazeutika, Taurin, Agrochemikalien, chemische Medizin und Aminosäuren.
Mehr anzeigen Grand Pharmaceutical Group Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Grand Pharmaceutical Group im Vergleich zum Marktanteil des Unternehmens? 512 grundlegende Statistiken Marktanteil HK$16.81b Gewinn(TTM ) HK$2.41b Umsatz(TTM ) HK$10.59b
7.0x Kurs-Gewinn-Verhältnis
1.6x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 512 Gewinn- und Verlustrechnung (TTM ) Einnahmen HK$10.59b Kosten der Einnahmen HK$4.34b Bruttogewinn HK$6.25b Sonstige Ausgaben HK$3.84b Umsatz HK$2.41b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 0.69 Bruttomarge 59.00% Nettogewinnspanne 22.75% Schulden/Eigenkapital-Verhältnis 28.1%
Wie hat sich 512 auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
5.4% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/02/21 03:44 Aktienkurs zum Tagesende 2025/02/21 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Grand Pharmaceutical Group Limited wird von 7 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
4 weitere Analysten anzeigen 
